Dendreon Corporation Announces Plans To Make PROVENGE® Commercially Available In Europe

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Dendreon Corporation today announced that it plans to make PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.

Hey, check out all the research scientist jobs. Post your resume today!

MORE ON THIS TOPIC